WO2007146946A2 - Matériaux implantables en cellulose microbienne pour réparation et régénération de tissu dur - Google Patents

Matériaux implantables en cellulose microbienne pour réparation et régénération de tissu dur Download PDF

Info

Publication number
WO2007146946A2
WO2007146946A2 PCT/US2007/071014 US2007071014W WO2007146946A2 WO 2007146946 A2 WO2007146946 A2 WO 2007146946A2 US 2007071014 W US2007071014 W US 2007071014W WO 2007146946 A2 WO2007146946 A2 WO 2007146946A2
Authority
WO
WIPO (PCT)
Prior art keywords
cellulose
microbial cellulose
agent
microbial
hard tissue
Prior art date
Application number
PCT/US2007/071014
Other languages
English (en)
Other versions
WO2007146946A3 (fr
Inventor
Gonzalo Serafica
Christopher Damien
Original Assignee
Xylos Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylos Corporation filed Critical Xylos Corporation
Publication of WO2007146946A2 publication Critical patent/WO2007146946A2/fr
Publication of WO2007146946A3 publication Critical patent/WO2007146946A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

  • This invention relates to polysaccharide materials and more particularly to microbial cellulose containing materials having suitable implantation properties for repair or replacement of hard tissue.
  • the invention also relates to the use of the implantable microbial cellulose as a bone void filler and as a carrier vehicle for active agent delivery for repair or regeneration of hard tissue.
  • Biologic materials used as bone void fillers include autograft tissue (a patient's own tissue), allograft (tissue from another individual of the same species) and xenograft (tissue from another species).
  • autograft tissue a patient's own tissue
  • allograft tissue from another individual of the same species
  • xenograft tissue from another species
  • Synthetic materials which include polylactic acid (PLA), polyglycolic acid (PGA), and polypropylene, have long been used as surgical sutures. These synthetic materials have been fabricated into films, mesh, and more complex three dimensional structures depending on the intended applications as described in U.S. Patent Nos. 5,441,508; 5,830,493; 6,031,148; 6,852,330; and 6,946,003.
  • Additional synthetic matrices consist of calcium based materials such as calcium phosphate in the form of hydroxyapatite, dicalcium phosphate or tricalcium phosphate; calcium carbonate in the form of calcite or aragonite; calcium sulfate, calcium aluminate and composites of these materials. These matrices demonstrate variable resorption rates and characteristics.
  • Other bone graft substitute materials include bioactive glasses and glass ceramics.
  • These synthetic materials possess certain physical characteristics that make them suitable as an implant material. Such properties include biocompatibility, strength, and chemical stability which can be particularly important for a specific application.
  • Biosynthetic materials have also been used for tissue repair and augmentation.
  • Chitosan for instance, can be considered biosynthetic in that it is produced by living organisms, i.e. certain shellfish. This material has been suggested for use in various medical implantable applications that include scaffolds for bone and soft tissue regeneration.
  • cellulose Another biomaterial that has had extensive use for surgical applications is cellulose and the use of viscose or regenerated cellulose as implantable articles.
  • tissue biocompatibility of cellulose and its derivatives Several investigators have studied tissue biocompatibility of cellulose and its derivatives (Miyamoto, T. et al., Tissue Biocompatibility of Cellulose and its derivatives. J. Biomed. Mat. Res., V. 23, 125-133 (1989)) and examined some specific applications for the material.
  • the oxidized form of regenerated cellulose has long been used as a hemostatic agent and adhesion barrier (Dimitrijevich, S. D., et al. In vivo Degradation of Oxidized regenerated Cellulose. Carbohydrate Research, V.
  • Biomat VoI 2 Pages 187-208 (1991)] describe a variety of materials for use as carriers for bone forming growth factors. These include collagen, hydroxyapatite, tricalcium phosphate, bioglasses and polymers such as polylactic acid and polyglycolic acid. They conclude that collagen may be an essential ingredient in the makeup of a carrier for optimal osteoinductive expression of osteoinductive agents. In their review there is no mention of cellulose, especially microbial cellulose and their conclusions suggest that any effective bone graft substitute with an active agent would require collagen.
  • U.S. Patent 5,563,124 describes an osteogenic product and process comprising calcium carbonate and a bone growth factor. Included are materials that also contain collagen, fibrin and alginate, but no mention of microbial cellulose is made.
  • U.S. Patent 5,558,861 the use of microbially-produced cellulose gel as a skin graft or vulnerary cover was described. The gel is in a form of a sheet of microbial cellulose which has been chemically modified and subjected to collagen treatment to enhance its ability to culture various types of cells. It did not disclose using the material as an orthopedic matrix material that can be loaded with useful agents such as BMP's. The patent also failed to disclose the use of microbial cellulose as an implantable medical device.
  • amorphous non-sheeted gel of microbial cellulose is described by Seraf ⁇ ca et al. in U.S. Patent Application 20040142019.
  • the amorphous gel is described as a wound dressing to which various agents could be added. Knowing that agents, including bone morphogenetic proteins, have demonstrated efficacy in the wound healing, this factor was included.
  • the application does not disclose any use of the gel or gel with factors in the repair of hard tissue when implanted into the body.
  • Microbial cellulose for use in dura replacement is described by Damien et al. in U.S. Patent Application 20050042263.
  • This material differs from the current invention in its application and in its composition: the dura material is in sheet form and can either be used as an onlay or sutured into place to repair soft tissue, while the material in the current invention is in a putty, gel or paste form that can be molded or packed into hard tissue defects for the repair of bone.
  • the cellulose in the above dura application has intact fibers, while those in the current invention are either chopped or grown in a non-fibrous form.
  • the material in the dura application has mechanical strength characteristics so as to hold a suture and/or to achieve a water-tight closure, while the current invention will not need to hold a suture and there is no required mechanical strength.
  • the current invention should calcify and form bone, while the material in the dura application should not demonstrate any calcification at the dural site.
  • the current application may be a composite with calcium salts, polymers, etc. and may deliver active agents; the dura application does not describe a composite or delivery of active agents.
  • Microbial cellulose for use in bone repair as a porous matrix combined with calcium salts is described in Hutchens et al. [U.S. Patent Application 20040096509].
  • their material is a porous polymer matrix that requires a minimum Young's modulus of lOGPa and a calcium salt within some of the pores.
  • the material in the instant invention is in a different form than that envisioned by Hutchins in that it may be chopped, milled or ground into a paste, gel or putty form that is moldable to fit into various sizes and shapes of bony defects. As such the instant invention has no strength requirement and can be much lower than the lOGPa and retain efficacy.
  • a lower GPa is actually preferred in the instant invention in that the material is not expected to be load bearing. Also there is no necessity of having a calcium salt with the cellulose. Rather it can be implanted as processed or materials including calcium salts or bioglasses can be admixed into the amorphous form without soaking or incubation in calcium and phosphate solutions. The resulting properties of the instant invention are therefore different from the Hutchens application.
  • an acceptable implantable material comprising microbial cellulose for use in hard tissue repair, regeneration or replacement applications.
  • an implantable material comprising microbial cellulose that is processed differently from previously described materials. This novel processing results in an implantable material with more desirable properties and that can be used in a wider variety of bony surgical applications in the orthopaedic, dental, periodontal, and craniomaxillo facial fields.
  • Methods of implanting microbial cellulose such as open, laparoscopic, arthroscopic, endoscopic, or percutaneous methods are also particularly desirable and attainable with a more conformable and flowable microbial cellulose containing material.
  • a new class of implantable materials utilizing microbial cellulose for use in medical and surgical applications of hard tissue repair, regeneration and replacement including bone void or defect filling and spine fusion.
  • methods of implanting microbial cellulose in a wide variety of applications that utilize the desirable physical and chemical properties of microbial cellulose are provided, in accordance with another preferred embodiment of the invention.
  • Yet another embodiment is a method for repairing hard tissue comprising implanting a microbial cellulose composition in a subject in need thereof, wherein the microbial cellulose composition comprises at least one agent for promoting hard tissue growth, said at least one agent being released in a controlled manner by the microbial cellulose.
  • Figure 1 Release of Bovine Serum Albumin from microbial cellulose over a 72- hour period.
  • Figure 2 Stiffness of cellulose paste samples with 5 and 10% cellulose with 1 minute processing time and 5% cellulose with 5 minute processing time.
  • Figure 3 BSA release profiles of cellulose paste samples with 5 and 10% cellulose with 1 minute processing time and 5% cellulose with 5 minute processing time.
  • Figure 4 PHMB release profiles of cellulose paste samples with 5 and 10% cellulose with 1 minute processing time, 5% cellulose with 5 minute processing time and 5% cellulose with 1 min processing time containing 10% hydroxyapatite.
  • Figure 5 Absorption profiles of cellulose paste samples with 5 and 10% cellulose with 1 minute processing time and 5% cellulose with 5 minute processing time.
  • Figure 6 Donation profiles of cellulose paste samples with 5 and 10% cellulose with 1 minute processing time and 5% cellulose with 5 minute processing time.
  • Figure 7 Stiffness of 5% cellulose paste samples (1 minute processing time) before drying, following drying with SCD and air-drying.
  • Figure 8 Table showing pH values of various paste formulations.
  • the present invention describes an implantable material comprised of microbial cellulose.
  • the instant implantable material has properties necessary for in vivo applications.
  • the implantable material of the instant invention is a paste that can be molded into a three-dimensional shape and possesses desired conformability characteristics.
  • the implantable materials of the instant invention are comprised of microbial cellulose.
  • microbial cellulose Those methods of preparing microbial cellulose are known to those of ordinary skill and are described, for example, in U.S. Patent Nos.
  • any cellulose producing organism can be used in producing the raw biosynthetic cellulose material.
  • biosynthetic cellulose produced from a static culture of Acetobacter xylinum is preferred.
  • the microbial cellulose content of the raw material is dependent on the amount of media supplied to the A.x. bacteria.
  • the cellulose may be cross-linked by irradiation or chemical means if its strength needs to be adjusted. Addition of other agents, such as glycerol, polyethylene glycol, Tween, chitosan, ethyl cellulose, hydroxypropyl cellulose or carboxymethyl cellulose can be used to modify the cellulose surface can also be performed in order to control water absorption and pliability which are desirable properties for implantable materials.
  • the material can remain wet, moist, partially dehydrated, or totally dehydrated by air, heat, lyophilization, freeze-drying or supercritical fluid drying. The material may be further processed by chopping, grinding or milling to a paste consistency.
  • the processed microbial cellulose will be further sterilized for applications as medical implantable articles using standard sterilization methods such as gamma irradiation, e-beam irradiation, ethylene oxide or steam sterilization.
  • the invention provides a method for preparing an implantable device for medical and surgical applications comprising the steps of providing a microbial cellulose material and incorporating said material into an implantable device for medical and surgical applications.
  • the microbial cellulose may be incorporated or fashioned into medical devices by commonly known methods such as molding, cross-linking, chemical surface reaction, dehydrating and/or drying, cutting or punching.
  • Such medical devices include tissue substitutes or scaffolds for repair or reinforcement of damaged hard tissue.
  • the instant microbial cellulose may be used as a scaffold in tissue engineering, substitution and replacement for hard tissue such as bone.
  • the instant microbial cellulose may be used as a substitute or scaffold in tissue engineering for orthopedic hard tissues such as bone.
  • the cellulose acts as a scaffold or trellis on which new tissue forms, orients and matures.
  • the invention provides a method of bone defect filling, consisting of an implantable composition comprising microbial cellulose and implanting said composition into a subject in need thereof.
  • the instant invention may be easily prepared as a dry or hydrated paste for direct application into bone voids. For this application the material must be conformable so as to fill the site and remain without dislocating.
  • the invention provides a method for use as an adjunct to achieve spine fusion.
  • the material must be moldable, easily implanted and remain in situ.
  • the material can be implanted alone or as a filler for spine cage implants or cadaveric femoral ring implants.
  • the invention provides a bone graft material that is degradable.
  • the cellulose is subjected to oxidation at various levels to render it bioresorbable. Depending on the level of oxidation the material can resorb in weeks to years. This resorption can be tailored to the rate of bone formation so that voids are not created by the material degrading too quickly.
  • the material can be used for repairing tissue in any bony site in the skeleton including dental and periodontal applications.
  • the microbial cellulose described can be processed using the methods described above to create a paste or gel that can be implanted to fill various sized bony defects.
  • the instant invention also contemplates an implantable composition comprising microbial cellulose and a medically useful agent.
  • Any number of medically useful agents for tissue repair can be used in the invention by adding the substances to an implantable composition comprising the microbial cellulose carrier, either at any step in the manufacturing process or directly to the final composition.
  • a medically useful agent is one having therapeutic, healing, curative, restorative or medicinal properties.
  • Such medically useful agents include collagen and insoluble collagen derivatives, hydroxyapatite and soluble solids and/or liquids dissolved therein.
  • amino acids, peptides, vitamins, co-factors for protein synthesis include hormones; endocrine tissue or tissue fragments; synthesizers; enzymes such as collagenase, peptidases, oxidases; cell scaffolds with parenchymal cells; angiogenic drugs and polymeric carriers containing such drugs; collagen lattices; biocompatible surface active agents, antigenic agents; cytoskeletal agents; cartilage fragments, living cells such as chondrocytes, bone marrow cells, mesenchymal stem cells, natural extracts, tissue transplants, bioadhesives, transforming growth factor (TGF-beta) and associated family proteins (bone morpho genetic protein (BMP), growth and differentiation factors (GDF) etc.), fibroblast growth factor (FGF), insulin- like growth factor (IGF-I) and other growth factors; growth hormones such as somatotropin; bone digestors; antitumor agents; f ⁇ bronectin; cellular attractants and attachment agents; immunosuppress
  • the drug can be in its free base or acid form, or in the form of salts, esters, or any other pharmacologically acceptable derivatives, enantomerically pure forms, tautomers or as components of molecular complexes.
  • the amount of drug to be incorporated in the composition varies depending on the particular drug, the desired therapeutic effect, and the time span for which the device is to provide therapy. Generally, for purposes of the invention, the amount of drug in the system can vary from about 0.0001% to as much as 60%.
  • the active agent may be used to reduce inflammation, increase cell attachment, recruit cells, and/or cause differentiation of the cells to repair the damaged tissue.
  • implantable materials using microbial cellulose may be applied in a number of other useful areas, including, but not limited to other hard tissue substitutes or scaffolds.
  • Other objects, features and advantages of the present invention will become apparent from the following examples. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. The invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.
  • Acetobacter xylinum microorganisms are cultured in a bioreactor containing a liquid nutrient medium at 30 degrees Celsius at an initial pH of 3-6.
  • the medium is based on sucrose or other carbohydrates.
  • the bioreactor is composed of a plastic box fitted with an airtight cover. Dimensions of the bioreactor measured 9 in x 13 in. Aeration ports are made in the bioreactor that allows the proper oxygen level to be achieved.
  • the fermentation process under static conditions is allowed to progress for a period of about 10-14 days, during which the bacteria in the culture medium produce an intact cellulose pellicle. Once the media is expended, the fermentation is stopped and the pellicle removed from the bioreactor.
  • the excess medium contained in the pellicle is removed by mechanical compression prior to chemical cleaning and subsequent processing of the pellicle.
  • the cellulose pellicle is subjected to a series of chemical wash steps to convert the raw cellulose film into a medical grade and non-pyrogenic implantable material. Processing starts with an 8% sodium hydroxide solution at 70-75 degrees Celsius for 1 hour, followed by a rinse in deionized water and then a soak in 0.25% hydrogen peroxide at 70-75 degrees Celsius for 1 hour.
  • the resulting films can be tested for pyrogens and mechanical properties.
  • the amount of cellular debris left in the cellulose pad after processing is measured by validated Limulus Amoebocyte Lysate (LAL) testing as outlined by the U.S. Food and Drug Administration (FDA) in 21 CFRlO.90.
  • LAL Limulus Amoebocyte Lysate
  • FDA U.S. Food and Drug Administration
  • the steps of the LAL test are defined by the test kit manufacturer and can simply be followed to yield the pyrogen level in the cellulose film.
  • the pellicles are mechanically pressed to reduce the water content.
  • the resulting pad is cut to shape and packaged.
  • Material can be prepared the same as in Example 1, with the added step of soaking in a 1% solution of bovine serum albumin (BSA) for 24 hours. Following saturation in the BSA solution the sample is placed in a 0.9% saline solution of 2Ox the sample mass. Aliquots are removed from the solution at various time points to determine the BSA release profile. The BSA concentration is assessed via ultraviolet/visible spectrophotometry. Figure 1 shows BSA was completely recovered following 72 hours in the saline solution indicating little to no binding of BSA to the cellulose.
  • BSA bovine serum albumin
  • Material can be prepared as per Example 1 , however prior to packaging the material can be placed in a Waring Blender with additional water to form a paste. Once processed the material is dehydrated by straining and then packaged. The fiber size can be controlled by blending time to result in materials with different physical properties. Samples containing 5% cellulose were made with processing times of one and five minutes. Stiffness testing was performed with a UNITED Tensile Tester using the circular bend procedure (ASTM Test Method D 4032). Samples were formed into discs with a diameter of between 3 and 4 cm with a thickness of between 5 and 7 mm. Stiffness values for one and five minutes processing were 5.6 ⁇ 1.7 and 2.3 ⁇ 0.7N, respectively, suggesting larger fiber sizes result in a more cohesive material.
  • Material can be prepared as per Example 3, however, an additional flow enhancer may be added to result in a moldable paste.
  • Tween, PEG, and carboxymethyl cellulose have been added to cellulose paste samples in concentrations ranging from 2.5 to 10% to alter the conformability characteristics of the pastes.
  • Example 5 A malleable paste containing 2.5% PEG 400, 10% hydroxyapatite (100-200 nm particle size), and approximately 4% cellulose.
  • Example 6 A malleable paste containing 5% carboxymethyl cellulose and 5% cellulose.
  • Material can prepared as in Example 3, however additional calcium salts (e.g. hydroxyapatite, tricalcium phosphate, calcium sulfate) can be added to form a composite paste.
  • Paste samples with 5 and 10% cellulose were made by incorporating 10, 15, 20 and 25% hydroxyapatite (HA).
  • Stiffness values ( Figure 2) and conformability were used to assess the handling properties of the composites. Stiffness values for composite samples with 5% cellulose increased 3- fold with the addition of 10% HA. Stiffness values remained constant with further increases in HA concentration, although conformability properties decreased.
  • 10% cellulose samples showed a 50% increase in stiffness with 10% HA and as seen with the 5% cellulose samples the stiffness remained constant with increases in HA and similar decreases in conformability were observed.
  • PHMB release profiles were determined with materials described in Example 3 and in addition a 5% cellulose sample with 10% HA was also evaluated. Samples were loaded by soaking in a 1% PHMB solution for 24 hours. After loading the individual samples were packed into a porous nylon sample bag and then placed in an aqueous solution with a volume 2Ox the mass of the paste sample. Aliquots were removed at various time points and analyzed with UV/Vis to determine the solution concentration which then could be used to determine the amount of PHMB remaining in the paste. Measurements were taken until the solution reached the theoretical equilibrium concentration. Figure 4 shows that the pure cellulose samples released PHMB at similar rates reaching equilibrium at 24 hours.
  • the HA containing sample still contains approximately 50% more PHMB at 24 hours indicating binding between HA and PHMB.
  • BSA release profiles of pure cellulose pastes there appears to be little interaction between the cellulose fibers and PHMB allowing for complete release in a pure cellulose formulation.
  • the addition of HA to the cellulose paste provides a means to control the release profile of the paste if there are specific interactions between additives.
  • Donation testing was performed by spreading between 2.5 and 3.5g of paste over a circular area on a 3in x 3in piece of pre-weighed smooth leather. Samples were removed after 2hr and the leather was reweighed to determine the quantity of moisture donated to the dry surface. Donation results were reported as a percentage of the initial weight of the sample, and are shown graphically in Figure 6. Donation decreased significantly upon increasing cellulose content to 10% from 5% cellulose. The addition of HA also affected the donation characteristics of the paste most pronounced in the 5% cellulose samples. Donation decreased approximately linearly with the additions of HA to the 5% cellulose samples resulting in an overall 80% decrease with the addition of 25% HA. Samples with 10% cellulose showed a 40% decrease irregardless of HA concentration.
  • Material can be prepared as described in Example 3 and dried under ambient conditions at elevated temperatures. After drying the resulting material is hard, brittle, and non-conforming. The stiffness of the air-dried material was determined and a 30-fold increase was observed compared to the stiffness of its non-dried counterpart, as shown in Figure 7
  • Example 12 Material can be prepared as described in Example 3 and dried using a supercritical drying (SCD) process with CO 2 .
  • SCD supercritical drying
  • the material first undergoes a solvent exchange process with methanol followed by the SCD processing.
  • the material is soft and spongy with a 3-fold increase in stiffness, with respect to the wet paste, illustrated in Figure 7.
  • Cellulose pastes comprised of 5% and 10% cellulose were made per Example 3. Samples containing PEG 400, Tween 80, and hydroxyapatite were prepared using the 5% cellulose paste. The pH of each sample was measured and is shown in Figure 8.
  • Cellulose paste materials with varying degrees of oxidation were produced with materials made per Example 1.
  • the cellulose films were incubated in solutions of varying sodium periodate to cellulose ratios including 0.8:1, 2:1, and 4:1.
  • Example 15 Incubation was conducted in closed reaction vessels at 30 degrees Celsius within a darkened incubator for approximately 17.5 hrs. Following incubation, the samples were placed in deionized water to extract unreacted sodium periodate. The oxidized cellulose pads were then subjected to a solvent exchange process with methanol, ground in a blender, and dried using the SCD process.
  • Example 15
  • Oxidized cellulose paste samples containing 3% cellulose were made with material as described in Example 3.
  • the cellulose pastes were incubated in solutions of varying sodium periodate to cellulose ratios including 0.8:1, 1.5:1, 2:1, and 4:1. Incubation was conducted in closed reaction vessels at 30 degrees Celsius within a darkened incubator for 16.5 to 17.5 hrs. Following incubation, the samples were placed in deionized water to extract unreacted sodium periodate. The oxidized cellulose pastes were then subjected to a solvent exchange process with methanol followed by SCD processing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne des matériaux en polysaccharide et plus particulièrement de la cellulose microbienne contenant des matériaux qui possèdent des propriétés d'implantation convenant pour la réparation ou le remplacement de tissu dur. L'invention concerne aussi l'utilisation de cellulose microbienne implantable comme matière de remplissage de vide osseux et comme véhicule transporteur pour délivrer un agent actif pour réparer ou régénérer un tissu dur.
PCT/US2007/071014 2006-06-13 2007-06-12 Matériaux implantables en cellulose microbienne pour réparation et régénération de tissu dur WO2007146946A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81296206P 2006-06-13 2006-06-13
US60/812,962 2006-06-13

Publications (2)

Publication Number Publication Date
WO2007146946A2 true WO2007146946A2 (fr) 2007-12-21
WO2007146946A3 WO2007146946A3 (fr) 2009-01-15

Family

ID=38713423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/071014 WO2007146946A2 (fr) 2006-06-13 2007-06-12 Matériaux implantables en cellulose microbienne pour réparation et régénération de tissu dur

Country Status (1)

Country Link
WO (1) WO2007146946A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079034A2 (fr) * 2006-12-24 2008-07-03 Politechnika Lodzka Biomatériau constitué de cellulose microbiologique à usage interne, procédé de production de ce biomatériau et utilisation dudit biomatériau en chirurgie des tissus mous et en chirurgie osseuse
EP2070557A1 (fr) * 2007-12-12 2009-06-17 Xylos Corporation Matériaux implantables à base de cellulose microbienne pour la réparation et la régénération de tissus durs
US7832857B2 (en) 2008-08-18 2010-11-16 Levinson Dennis J Microbial cellulose contact lens
DE102009024133A1 (de) 2009-06-04 2010-12-09 Jenpolymer Materials Ltd. & Co. Kg Bakterielle Nanocellulose zur Knorpelneubildung
DE102012003541A1 (de) 2012-02-21 2013-08-22 Jenpolymer Materials Ltd. & Co. Kg Bakterielle Nanocellulose-Körper mit kanalartiger Hohlraumstruktur sowie deren Herstellung und Verwendung

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074690A1 (fr) * 1999-06-07 2000-12-14 Wright Medical Technology, Inc. Composition de substitut de greffe osseuse
US20040096509A1 (en) * 2002-11-15 2004-05-20 Hutchens Stacy A. Composite material
US20040142019A1 (en) * 2003-01-16 2004-07-22 Xylos Corporation Microbial-derived cellulose amorphous hydrogel wound dressing
WO2006017729A2 (fr) * 2004-08-05 2006-02-16 Xylos Corporation Oxydation de la cellulose par dioxyde d’azote dans un solvant d’amine tertiaire perfluoré
EP1795213A2 (fr) * 2005-12-02 2007-06-13 Xylos Corporation Matériaux implantables à base de cellulose microbienne pour applications médicales diverses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074690A1 (fr) * 1999-06-07 2000-12-14 Wright Medical Technology, Inc. Composition de substitut de greffe osseuse
US20040096509A1 (en) * 2002-11-15 2004-05-20 Hutchens Stacy A. Composite material
US20040142019A1 (en) * 2003-01-16 2004-07-22 Xylos Corporation Microbial-derived cellulose amorphous hydrogel wound dressing
WO2006017729A2 (fr) * 2004-08-05 2006-02-16 Xylos Corporation Oxydation de la cellulose par dioxyde d’azote dans un solvant d’amine tertiaire perfluoré
EP1795213A2 (fr) * 2005-12-02 2007-06-13 Xylos Corporation Matériaux implantables à base de cellulose microbienne pour applications médicales diverses

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079034A2 (fr) * 2006-12-24 2008-07-03 Politechnika Lodzka Biomatériau constitué de cellulose microbiologique à usage interne, procédé de production de ce biomatériau et utilisation dudit biomatériau en chirurgie des tissus mous et en chirurgie osseuse
WO2008079034A3 (fr) * 2006-12-24 2008-10-23 Politechnika Lodzka Biomatériau constitué de cellulose microbiologique à usage interne, procédé de production de ce biomatériau et utilisation dudit biomatériau en chirurgie des tissus mous et en chirurgie osseuse
EP2070557A1 (fr) * 2007-12-12 2009-06-17 Xylos Corporation Matériaux implantables à base de cellulose microbienne pour la réparation et la régénération de tissus durs
US7832857B2 (en) 2008-08-18 2010-11-16 Levinson Dennis J Microbial cellulose contact lens
DE102009024133A1 (de) 2009-06-04 2010-12-09 Jenpolymer Materials Ltd. & Co. Kg Bakterielle Nanocellulose zur Knorpelneubildung
DE102012003541A1 (de) 2012-02-21 2013-08-22 Jenpolymer Materials Ltd. & Co. Kg Bakterielle Nanocellulose-Körper mit kanalartiger Hohlraumstruktur sowie deren Herstellung und Verwendung

Also Published As

Publication number Publication date
WO2007146946A3 (fr) 2009-01-15

Similar Documents

Publication Publication Date Title
EP1795213B1 (fr) Procédé de production des matériaux implantables à base de cellulose microbienne pour applications médicales diverses
Naahidi et al. Biocompatibility of hydrogel-based scaffolds for tissue engineering applications
Puppi et al. Polymeric materials for bone and cartilage repair
US5139527A (en) Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation
US7892572B2 (en) Orthopaedic materials derived from keratin
US20040259972A1 (en) High density fibrous polymers suitable for implant
US20080260801A1 (en) Composite material, especially for medical use, and method for producing the material
JP6195851B2 (ja) 吸収性セルロース系生体材料及びインプラント
EP2932989B1 (fr) Produit d'étanchéité de tissu, dans lequel sont mélangés du collagène et de la fibrine, et son procédé de préparation
CN101098718A (zh) 壳聚糖组合物
US20070286884A1 (en) Implantable microbial cellulose materials for hard tissue repair and regeneration
CN111432853A (zh) 交联的蛋白质泡沫及其使用多用途细胞支架的方法
JP5879459B2 (ja) 親水性のホスフェートグループを含有する脱水された部分的に精製された骨置換材料
US20100297239A1 (en) Osseointegrative meniscus and cartilage implants based on beta-glucan nanocomposites
Claudio-Rizo et al. Study of the polyacrylate interpenetration in a collagen-polyurethane matrix to prepare novel hydrogels for biomedical applications
WO2007146946A2 (fr) Matériaux implantables en cellulose microbienne pour réparation et régénération de tissu dur
WO2011064724A1 (fr) Matériaux composites biomimétiques, leur procédé de préparation et leur utilisation en vue de la production de structures monocouches, bicouches ou multicouches servant à la régénération des tissus osseux, cartilagineux et ostéocartilagineux
EP2070557A1 (fr) Matériaux implantables à base de cellulose microbienne pour la réparation et la régénération de tissus durs
AU2007304237B2 (en) Matrix gel graft without cells
EP4142816B1 (fr) Méthode de préparation d'un échafaudage tridimensionnel à usage médical
EP2379006A1 (fr) Matériaux implantables pour fixation tissulaire minimale
O’Brien The development of novel scaffolds for tissue engineering with a range of structural and mechanical properties
CN110251730A (zh) 一种多孔复合骨架及其制备方法
WO2017205740A1 (fr) Procédé de préparation d'une matrice de régénération tissulaire
Arshad et al. Succinic Acid functionalized, Silk Fibroin and Hydroxyapatite Based Scaffolds for Craniofacial Deformity Repair

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812117

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 23-02-09

122 Ep: pct application non-entry in european phase

Ref document number: 07812117

Country of ref document: EP

Kind code of ref document: A2